Elevated liver enzymes, often discovered incidentally during routine bloodwork, present a common yet complex issue in clinical practice. The challenge lies in identifying the underlying cause and managing it effectively.
Increased liver enzymes, specifically Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST), indicate hepatocellular injury. However, these elevations can stem from a myriad of conditions, including viral hepatitis, alcohol-induced liver disease, non-alcoholic fatty liver disease (NAFLD), and drug-induced liver injury.
A comprehensive history and physical examination are crucial initial steps. They may reveal risk factors such as alcohol consumption, medication use, or signs of chronic liver disease. If the etiology remains unclear, serologic testing can help identify viral hepatitis or autoimmune liver disease. Imaging studies, especially ultrasound, can detect structural abnormalities or fatty infiltration. In some cases, liver biopsy may be necessary.
Management primarily involves addressing the underlying cause. For instance, alcohol abstinence is advised in alcohol-related liver disease, while weight loss and control of metabolic risk factors are key in NAFLD. Certain drug-induced liver injuries may require discontinuation of the offending agent. In viral hepatitis, antiviral therapy is the mainstay of treatment.
Regular follow-up with liver function tests is essential to monitor the response to treatment and detect any progression of the disease. In some cases, referral to a hepatologist may be necessary for further management.
In conclusion, the management of elevated liver enzymes necessitates a comprehensive, patient-centered approach. Understanding the various potential causes, employing a systematic diagnostic strategy, and tailoring management to the specific etiology can lead to successful patient outcomes.
1.
Researchers use genomic technology to investigate aggressive skin cancer linked to burn scars
2.
The Growing Role of AI in Cancer Treatment
3.
Tafasitamab Regimen Improves PFS in Relapsed/Refractory Follicular Lymphoma
4.
Lower Prostate Cancer Mortality Linked to Unavailable Clinical Trials.
5.
Powerlifting through breast cancer: How a breast cancer survivor defied chemotherapy with strength training
1.
Drug Exposure in Tumor Microenvironments: Mechanisms, Clinical Implications, and Emerging Strategies
2.
Proteoform Networks in Blood Disorders: Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies
3.
Antibody-Drug Conjugates and the Dawn of Targeted Cancer Therapy in 2025
4.
Revolutionizing Oncology Trials: Optimization, Matching, Diversity, and Decentralization
5.
Direct Oral Anticoagulants (DOACs) in Atrial Fibrillation: A Comprehensive Review
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion- Part II
2.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
3.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
4.
How Multidisciplinary Teams Support Modern Cancer Care
5.
Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation